Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Theravance Biopharma's Gross Margin % or its related term are showing as below:
During the past 13 years, the highestGross Margin % of Theravance Biopharma was 98.82%. The lowest was 60.81%. And the median was 94.05%.
FRA:0TB's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.9 * Ranked among companies with meaningful Gross Margin % only.
Theravance Biopharma had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Theravance Biopharma was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Theravance Biopharma had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Theravance Biopharma Gross Margin % Related Terms
Theravance Biopharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for Theravance Biopharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0TB vs ABUS, SANA, ANNX: Gross Margin % Comparison
For the Biotechnology subindustry, Theravance Biopharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theravance Biopharma Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Theravance Biopharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Theravance Biopharma (FRA:0TB) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Theravance Biopharma and its competitors. Over the past decade, Theravance Biopharma's Gross Margin % has ranged from 60.81 to 98.82. According to the industry distribution chart, Theravance Biopharma ranks #999999 out of 733 companies in the Biotechnology industry.
Is Theravance Biopharma's Gross Margin % too high?
Theravance Biopharma's current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 60.81 to a high of 98.82. Based on the distribution chart, Theravance Biopharma ranks #999999 out of 733 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's Gross Margin % compare to ABUS and SANA?
According to the Biotechnology industry distribution chart, Theravance Biopharma ranks #999999 out of 733 companies for Gross Margin %. This places Theravance Biopharma in the lower half of its industry. The industry median Gross Margin % is 60.90. Historically, Theravance Biopharma's own Gross Margin % has ranged from 60.81 to 98.82 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Theravance Biopharma and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theravance Biopharma's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (FRA:0TB) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.18, compared to a current price of €14.60 — trading 9.8% below its estimated fair value. The current Gross Margin % is 0.00%. Theravance Biopharma's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Theravance Biopharma (FRA:0TB), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theravance Biopharma (FRA:0TB) Overvalued in 2026?
Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued.
The current stock price of €14.60 is trading 9.8% below its estimated GF Value™ of €16.18.
GuruFocus considers Theravance Biopharma to be Modestly Undervalued.
Key valuation signals for FRA:0TB:
Gross Margin %: 0.00%
GF Value™: €16.18 vs. price of €14.60 (9.8% below fair value)
No single metric tells the full story. See the FRA:0TB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score
Get the complete analysis for FRA:0TB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0TB has been successfully added to your 
